Artículos

Permanent URI for this collectionhttps://dspace-test.ucuenca.edu.ec/handle/123456789/21983

Browse

Browsing Artículos by Author "Abad Polo, Paula Gabriela"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Cardiomyopathy in patients with liver cirrhosis: review article
    (2022) Gonzalez Dominguez, Esteban Horacio; Cordova Reyes, Diego Andres; Abad Polo, Paula Gabriela; González, Juan Eduardo; Gonzalez Dominguez, Camila Maria; Cordero Cedillo, Juan Jose
    Cirrhotic cardiomyopathy is a complication in cirrhotic patients, with a prevalence of more than 40%. During the resting state, it is a subclinical entity, which triggers symptoms upon exercise or circulatory Cirrhotic cardiomyopathy is a complication in cirrhotic patients, with a prevalence of more than 40%. During the resting state, it is a subclinical entity, which triggers symptoms upon exercise or circulatory
  • Thumbnail Image
    Item
    Evaluación del valor diagnóstico de la calprotectina fecal en pacientes con dispepsia
    (2022) Gonzalez Dominguez, Camila Maria; Vasquez Moscoso, Ana Isabel; Cordova Reyes, Diego Andres; Abad Polo, Paula Gabriela; González, Juan Eduardo; Lopez Dominguez, Guillermo Estuardo; Cordero Asanza, Juan Jose; Gonzalez Dominguez, Esteban Horacio
    The diagnosis of patients with dyspepsia represents a challenge since in most cases complex and costly endoscopic observations are required. In this study, we evaluated the diagnostic role of fecal calprotectin in patients with dyspepsia. To this end, an observational study was performed in 2019 on 149 patients with dyspepsia registered in the private Gastroenterology Specialists Center in Cuenca, Ecuador. The available data encompassed age, sex, alarm signs, fecal calprotectin (FC) values, and endoscopic findings. Patients in the age group >65 years were most represented, 56.4% of the population were female, 48.57% were FC positive of whom 86.8% possessed significant values of FC. FC+ was significantly associated with findings by EDA/colonoscopy (p<0.001). The most diagnostic pathologies in patients with FC+ were congestive gastropathy, intestinal metaplasia, giardiasis, and polyposis. FC correlated positively with the presence of pathological findings in the invasive diagnostic tests (r=0.298) and is a useful, noninvasive biomarker correlating positively with endoscopic findings in the gastrointestinal tract of dyspepsia patients.
  • Thumbnail Image
    Item
    Protocolo de inmunosupresión en trasplante hepático: revisión de la literatura.
    (2022) Gonzalez Dominguez, Esteban Horacio; Cordova Reyes, Diego Andres; Abad Polo, Paula Gabriela; González, Eduardo; Gonzalez Dominguez, Camila Maria; Cordero Velastegui, Juan Jose; Flores Siguenza, Luis Francisco; Aguirre Bermeo, Hernan Marcelo
    Liver transplantation is the last option for the treatment of liver disease. Immunosuppression schemes are required to avoid graft rejection, which have evolved over the years. A literature review was carried out in PubMed on the immunosuppressive therapies available to avoid graft rejection in liver transplantation, as well as on the schemes used, adverse effects, interactions and their modifications from the induction phase to subsequent follow-up. The usual induction was found to be with steroids or clonal immune therapy. In maintenance, calcineurin inhibitors are the most widely used, and their doses should be adjusted according to their serum levels and the presence of adverse effects such as nephrotoxicity or diabetes. On the other hand, mTOR inhibitors have been considered to reduce the risk of hepatocellular cancer recurrence. The characteristics of the patient and their comorbidities (pregnancy, kidney failure, diabetes, sepsis, hepatocellular carcinoma) require modification and individualization of the treatment
  • Thumbnail Image
    Item
    Trastornos de la coagulación en cirrosis hepática: artículo de revisión
    (2022) Abad Polo, Paula Gabriela
    The pathophysiological events of liver cirrhosis drastically alter the processes of primary and secondary hemostasis and fibrinolysis. Previously, it was conceptualized that these alterations exclusively predisposed to hypocoagulation, due to the low hepatic production of procoagulant factors and the characteristic thrombocytopenia. Currently, there is evidence of compensation mechanisms that lead to a hemostatic rebalancing, which is unstable and easily dysregulated in the presence of comorbidities, complications and progression of the disease, leading to prohemorrhagic or prothrombotic phenomena, such as portal vein thrombosis, venous thromboembolism, etc. To effectively determine whether a cirrhotic patient is at risk for bleeding, conventional coagulation tests are not helpful. Treatment will depend on the hypo or hypercoagulable state of the patient. In this manuscript, we review the hemostatic phenomena in cirrhosis, to reveal its characteristics, effective diagnostic methods and treatment